80% of Empiric Therapy is unnecessary.  The high negative predictive value of β-D-Glucan cuts this over-use dramatically.

    Intravenous antifungal agents are commonly prescribed empirically for patients at risk of invasive fungal infections.  Yet around 80% of empirically prescribed antifungal treatments are shown to be unnecessary with no evidence of Invasive Fungal Infection. The high negative predictive value of β-D-Glucan cuts this over-use dramatically..

    would you like a precis of key publications?  Use  the contact form below​

    These are from posters presented at a meeting in Aberdeen in October 2021 relevant to rapid fungal diagnostics & antifungal stewardship.
    P356 - A retrospective review of the AFS at Leicester.
    Absolute antifungal expenditure showed an annual decrease of £320,600
    P222 - A multi-site evaluation of antifungal use- implications for AFS.     ''β-D-glucan utilization is greatest when turn-around-time is shortest​''
    P062 - Introduction of β-D-glucan testing.
    ​Based on bringing 256 tests in-house there was a saving of £75,000 in therapy.
    Would you like abstracts of these presentations?  There are more - use the contact form below.

    Minimising laboratory turnaround times is key to unlocking the potential of β-D-Glucan. ​ Patient to result in under 2 hours is now possible.

    FACIS, Fully Automatic Chemiluminescence ​Immunoassay System, has the key attributes of being simple and economical to use making a 24/7 service for β-D-Glucan/Galactomannan testing a real possibility. 

    If you would like any of the following,
    ​
    DOCUMENTS   Product Information, Comparison with competitors, Evaluations, Certifications.
    Zoom/Team presentation
    Product demonstration
    Telephone call

    Make use of the contact form below​ .
    Antifungal Stewardship + rapid TAT biomarkers might save your hospital £100,000 per year.